학술논문

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Document Type
Article
Source
In Annals of Oncology December 2020 31(12):1734-1745
Subject
Thoracic tumors
Language
ISSN
0923-7534